Cannabis firm Tilray (NASDAQ:TLRY) has confirmed it will make cuts to its workforce in an attempt to reduce costs following a grueling year for investments in the space.

The company, based out of Nanaimo, British Columbia, told media outlets on Tuesday (February 4) that a 10 percent reduction will be needed in order to reach profitability, a goal of the company.


“The tough decision to eliminate roles has not been taken lightly,” Brendan Kennedy, CEO of Tilray, said in a statement to the Financial Post. “We’re extremely grateful to our past and current employees for their contributions.”

While Tilray initially saw a jump in value during Tuesday’s trading session, finishing at a share price of US$18.15, the company had dropped to US$17.83 as of 1:28 p.m. EST on Wednesday (February 5).

Outside of this week’s news, Tilray has seen a jump in market sentiment recently thanks to the addition of a new chief operating officer in Jon Levin, an ex-Revlon (NYSE:REV) commercial executive, and a new CFO in Michael Kruteck. Kruteck previously served with privately held Pharmaca Integrative Pharmacy and Molson Coors Beverage (NYSE:TAP,TSX:TAP) before that.

The luminary hires were touted as bringing expertise that would bolster the company’s plans.

Tilray’s cuts are the latest instalment in a slew of job losses seen across the board for public cannabis companies. Lately investors have seen companies such as HEXO (NYSE:HEXO,TSX:HEXO) and CannTrust Holdings (NYSE:CTST,TSX:TRST) cut down on workforce numbers.

The company is also not the only one to roll out new leading executives this year. Firms like Sundial Growers (NASDAQ:SNDL), TerrAscend (CSE:TER,OTCQX:TRSSF) and The Supreme Cannabis Company (TSX:FIRE,OTCQX:SPRWF) have all seen unexpected changes in their CEO positions.

Kennedy received the distinction of becoming one of the biggest winners of the cannabis boom. In 2018, Bloomberg awarded the Tilray CEO the second spot on its highest-paid CEO list.

He was right behind Elon Musk, CEO of Tesla (NASDAQ:TSLA), on the top five list, which also included Bob Iger, CEO and chairman of Walt Disney (NYSE:DIS); Tim Cook, CEO of Apple (NASDAQ:AAPL); and Nikesh Arora, CEO and chairman of Palo Alto Networks (NYSE:PANW).

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

NYSE | TSX: ACB

Aurora Cannabis Inc. (“Aurora” or the “Company”) (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today has announced today that it has entered into an agreement with a syndicate of underwriters led by BMO Capital Markets and ATB Capital Markets, under which the underwriters have agreed to buy on bought deal basis 12,000,000 units of the Company (the “Units”), at a price of US$10.45 per Unit for gross proceeds of approximately US$125 million (the “Offering”). Each Unit will be comprised of one common share of the Company (a “Common Share”) and one half of one common share purchase warrant of the Company (each full common share purchase warrant, a “Warrant”). Each Warrant will be exercisable to acquire one common share of the Company (a “Warrant Share”) for a period of 36 months following the closing date of the Offering at an exercise price of US$12.60 per Warrant Share, subject to adjustment in certain events.

Keep reading... Show less

Trading resumes in:

Company: Revive Therapeutics Ltd.

Keep reading... Show less

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES /

Revive Therapeutics Ltd. (” Revive ” or the ” Company “) (CSE:RVV) ( USA : RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has entered into an amended agreement with Canaccord Genuity Corp. and Leede Jones Gable Inc. as the co-lead underwriters (collectively, the ” Underwriters “), to increase the size of its previously announced offering of units (the ” Equity Units “) at a price of $0.50 per Equity Unit. Under the amended terms, the Underwriters have agreed to purchase, on a bought deal basis, 40,000,000 Equity Units for gross proceeds to the Company of $20,000,000 (the ” Offering “). The over-allotment option granted to the Underwriters will proportionately increase to 15% of the Offering.

Keep reading... Show less

The new dispensary brings expanded access for patients in the growing communities of Central Florida

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 77th nationwide. The new, 5,100 sq. ft. location marks the Company’s first in Summerfield expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”).

The Company announced today that its board of directors have approved a private placement of up to 15,000,000 units at a price of $.40 per unit for gross proceeds of up to $6,000,000. Each unit will consist of one common share of the Company and one share purchase warrant. Each share purchase warrant will be exercisable to purchase an additional common share at a fixed price of $.45 per share for a period of one year from closing.

Keep reading... Show less